Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 779-784    DOI: 10.31083/j.ejgo.2020.05.5045
Original Research Previous articles | Next articles
Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer
Lingyun Zhai1, Lixin Zeng2, Hongru Jiang3, Wei Li2, *()
1Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China
2Department of Gynecology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, P. R. China
3Department of Gynecology, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, P. R. China
Download:  PDF(2136KB)  ( 88 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
This study evaluated the effectiveness of SC-560 (a cyclooxygenase-1-selective inhibitor) in combination with taxol or cisplatin (DDP) in mice bearing SKOV-3 human ovarian carcinoma xenograft. Cyclin D1 expression, apoptotic index, and vascular endothelial growth factor (VEGF) mRNA level in tumor tissues were determined by immunohistochemistry, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling assay, and reverse transcription-polymerase chain reaction, respectively. Cyclin D1 and VEGF mRNA expression were inhibited, whereas the apoptotic index was markedly increased in the therapeutic group (all p < 0.05 in comparison with the control). The group of SC-560 + taxol had synergistic effects on suppressing cyclin D1 and VEGF expression and promoting apoptosis in comparison to SC-560 or taxol alone (p < 0.05). Compared with SC-560 or DDP group, SC-560 + DDP treatment made a greater reduction on level of VEGF mRNA (p < 0.05). The results of this study revealed that the combined therapy of SC-560 and taxol had synergistic effects on suppression of cyclin D1 and VEGF expression, and apoptosis-promoting in mice bearing SKOV-3 human ovarian carcinoma xenografts.
Key words:  Epithelial ovarian cancer      SC-560      Cisplatin      Taxol      Cyclin D1      Apoptosis      Vascular endothelial growth factor     
Submitted:  13 October 2018      Accepted:  02 May 2019      Published:  15 October 2020     
*Corresponding Author(s):  WEI LI     E-mail:  wei5901482@hotmail.com

Cite this article: 

Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5045     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/779

[1] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[2] Tao Wei, Mei-Hua Gao, Ying Li. Effect of CD59-targeted multi-directional intervention on transmembrane apoptotic signal transduction of cervical cancer HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 713-719.
[3] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[4] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[5] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[6] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[7] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[8] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[9] K. Takeuchi, M. Sawada, A. Takeda, A. Yoshida, M. Sugimoto, M. Fujita, H. Morita. Juvenile granulosa cell tumor with massive ascites: A case report and immunohistochemical study of ascites formation[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 281-283.
[10] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[11] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[12] J. Zheng, P. Liu, C. Li, L. Cheng, Y. Xu, F. Guo, M. Xiong, T. Song, Y. Li, F. Yan, H. Xu, B. Chen, J. Zhang. Umbilical cord-derived mesenchymal stem cells efficiently induced apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 839-845.
[13] T. Hanikezi, W. Shaadaiti, A. Mayinuer, J.D. Zhao, M. Guzainuer, A. Mourboul, A. Zufeiya. Impacts of isoliquiritigenin on proliferation and apoptosis of human cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 425-430.
[14] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma - case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[15] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .